Nifuroxazide in initial therapy for acute intestinal infections in adults

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2021-01-01 DOI:10.20953/1729-9225-2021-3-146-152

A. Garbuzov, P. Chukhliaev, D. Khavkina, N. Meshkova, T. Ruzhentsova

{"title":"Nifuroxazide in initial therapy for acute intestinal infections in adults","authors":"A. Garbuzov, P. Chukhliaev, D. Khavkina, N. Meshkova, T. Ruzhentsova","doi":"10.20953/1729-9225-2021-3-146-152","DOIUrl":null,"url":null,"abstract":"The article presents the results of the meta-analysis of the effectiveness of nifuroxazide in the treatment of acute intestinal infections in adults. Objective. To summarize the results of studies evaluating the efficacy and safety of nifuroxazide in acute intestinal infections in adults. Materials and methods. A search was carried out in electronic databases and among paper-based information in accordance with modern requirements for conducting meta-analysis. We selected high-quality randomized and non-randomized clinical trials, in which nifuroxazide was compared with placebo, an alternative antibiotic, or with the absence of antibacterial therapy in the treatment of acute intestinal infections in adults from 18 to 90 years of age. In most studies, the compared medications were prescribed together with other therapies: formulations for rehydration, enterosorbents, and probiotics. Results. A total of 1999 people participated in the studies selected for analysis (541 – in the main group, 1458 – in the comparison group). It was shown that nifuroxazide significantly reduced the duration of diarrhea in acute intestinal infections adults, on average, by 1,35 days. When prescribing nifuroxazide, there was no increase in intoxication, symptoms of gastrointestinal mucosa irritation (nausea, vomiting), and allergic reactions. Conclusion. The meta-analysis confirmed the effectiveness of nifuroxazide in acute intestinal infections in adults. Key words: antibacterial therapy, adults, diarrhea, intoxication, fever, nifuroxazide, acute intestinal infections","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"36 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2021-3-146-152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The article presents the results of the meta-analysis of the effectiveness of nifuroxazide in the treatment of acute intestinal infections in adults. Objective. To summarize the results of studies evaluating the efficacy and safety of nifuroxazide in acute intestinal infections in adults. Materials and methods. A search was carried out in electronic databases and among paper-based information in accordance with modern requirements for conducting meta-analysis. We selected high-quality randomized and non-randomized clinical trials, in which nifuroxazide was compared with placebo, an alternative antibiotic, or with the absence of antibacterial therapy in the treatment of acute intestinal infections in adults from 18 to 90 years of age. In most studies, the compared medications were prescribed together with other therapies: formulations for rehydration, enterosorbents, and probiotics. Results. A total of 1999 people participated in the studies selected for analysis (541 – in the main group, 1458 – in the comparison group). It was shown that nifuroxazide significantly reduced the duration of diarrhea in acute intestinal infections adults, on average, by 1,35 days. When prescribing nifuroxazide, there was no increase in intoxication, symptoms of gastrointestinal mucosa irritation (nausea, vomiting), and allergic reactions. Conclusion. The meta-analysis confirmed the effectiveness of nifuroxazide in acute intestinal infections in adults. Key words: antibacterial therapy, adults, diarrhea, intoxication, fever, nifuroxazide, acute intestinal infections

查看原文本刊更多论文

呋噻嗪对成人急性肠道感染的初步治疗

这篇文章介绍了硝呋噻治疗成人急性肠道感染有效性的荟萃分析结果。目标。总结评价硝呋沙嗪治疗成人急性肠道感染的有效性和安全性的研究结果。材料和方法。根据进行荟萃分析的现代要求，在电子数据库和纸质信息中进行了检索。我们选择了高质量的随机和非随机临床试验，将nifuroxazide与安慰剂(一种替代抗生素)或不使用抗菌药物治疗18 - 90岁成人急性肠道感染进行比较。在大多数研究中，比较的药物与其他疗法一起开处方:补液配方、肠吸收剂和益生菌。结果。总共有1999人参加了被选中进行分析的研究(主要组541人，对照组1458人)。结果表明，硝呋唑胺可显著减少急性肠道感染成人腹泻持续时间，平均减少1.35天。开硝呋昔德时，中毒、胃肠道黏膜刺激症状(恶心、呕吐)和过敏反应均未增加。结论。荟萃分析证实了硝呋噻治疗成人急性肠道感染的有效性。关键词:抗菌治疗，成人，腹泻，中毒，发热，硝呋噻，急性肠道感染

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.